Avecia sells Pharmaceuticals business unit to Nicholas Piramal India Ltd
Avecia announced that it has signed a definitive agreement to sell its Pharmaceutical custom synthesis business to Nicholas Piramal India Ltd for GBP 9.5 million. The transaction, which will fund the business' UK pension fund deficit of between GBP 8 - 9 m, is subject to regulatory and other closing conditions. In 2004, the business recorded sales of GBP 36 million.
The sale includes all Avecia Pharmaceuticals' assets and operations at its principal UK site in Huddersfield, England, a large scale fermentation asset at Billingham, England, a High Potency Substance (HPS) facility at Grangemouth in Scotland and its North American operation - Torcan Chemicals in Aurora, Canada. All 350 Avecia Pharmaceuticals' employees are included in the transaction.
David Killworth, Vice President Avecia Pharmaceuticals said: "I am delighted that we will be joining forces with Nicholas Piramal India Ltd to create a major new force in the custom synthesis business. This transaction brings together the strengths of Indian and Western operations to provide a total lifecycle solution which addresses the changing requirements of the global pharmaceutical and biotechnology sectors".
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.